Chicago, IL – November 5, 2020 – Svoboda Capital Partners, LLC (“SC”), is pleased to announce the recapitalization of Clarion Healthcare (“Clarion”). Specific terms of the transaction were not disclosed.

Clarion, founded in 2003 and based in Boston, MA, provides strategic and organizational consulting services to life sciences companies. As part of its client engagements, Clarion helps biotech / pharma companies envision the opportunity for their assets, craft strategies to ensure success, and enable organizational excellence to realize value creation opportunities. Clarion serves clients spanning the size spectrum – from leading global enterprises to emerging firms seeking to commercialize their first asset. Over the years, Clarion has developed deep therapeutic area domain expertise, with a strong presence in oncology, rare diseases, and other specialty therapeutic areas, including ophthalmology, dermatology, and endocrinology, among others.

Clarion Co-founder Tom Murtagh has assumed the role of Chief Executive Officer (CEO). The leadership team is rounded out by fellow Managing Directors Bart Lombardi (Co-founder), Carol Kearney, Dominick Mastropoalo, Dennis Chang, and Bobby Moy; Principal, Alyssa Trigger; Director of Finance and Operations, Jen Fennessy; and Director of Talent & Culture Development, Jennifer Kuhn.

“Since Clarion’s inception, our mission has been to positively impact our clients by helping them tackle their toughest and most critical challenges with our fit-for-purpose strategic guidance,” said Murtagh. “We accomplish this through a unique combination of entrepreneurial spirit, a rigorous scientific and analytic foundation, and a deep commitment to collaboration. SC truly understands and appreciates the importance of our people and culture, which is one of the reasons why we are so excited to partner with the SC team for our next phase of growth.”

“Helping build and grow Clarion alongside so many incredible colleagues and clients has been a privilege,” said Lombardi. “Our passion for finding opportunities where others see challenges has enabled us to consistently advance our clients’ organizations while developing meaningful, long-term relationships. Our partnership with SC will help catalyze Clarion’s growth and find additional ways to deliver long-term value to clients.”

“Clarion is a very impressive organization, delivering high value to clients by bridging the intersection between science and medical know-how with business acumen and commercialization expertise. Our partnership with Clarion is consistent with our firm’s continued focus on investing in and helping build great professional service companies – key tenets of which include preserving culture and reputation while providing the capital and support to help enhance growth,” reflected Ryan Kantor, Vice President at SC.

For more information on Clarion, please visit www.clarionhealthcare.com